Women carrying higher levels of two common “forever chemicals” in their blood faced a much higher rate of an aggressive, hard-to-treat breast cancer, according to a new federal analysis.
Quick Take
- A National Institutes of Health (NIH) study found higher blood levels of PFOA and PFOS linked to more cases of ER-negative breast cancer, a tougher subtype to treat.
- Women with the highest PFOA levels had a 67% higher rate of this cancer type; those with the highest PFOS levels had a 93% higher rate.
- Researchers measured chemical levels in blood drawn years before diagnosis, using data from the long-running Sister Study of over 50,000 women.
- The link did not show up for breast cancer overall, only for the ER-negative subtype, and the study cannot prove the chemicals caused the cancer.
What The NIH Study Actually Found
Researchers at the NIH tested blood samples for 17 different PFAS chemicals, collected before any woman in the study developed cancer. Two chemicals stood out: perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS). Women with the highest levels of these chemicals developed ER-negative breast cancer at notably higher rates than women with the lowest levels, according to the NIH’s own release on the findings.
ER-negative breast cancer is the subtype that does not feed on estrogen. That matters because it rules out hormone-blocking drugs like tamoxifen, leaving doctors with fewer treatment tools. It also tends to be more aggressive and harder to catch early. A chemical exposure tied specifically to this subtype deserves serious attention, not a shrug.
Why This Study Carries More Weight Than A Typical Headline
This was not a quick survey or a lab rat experiment. Researchers used the Sister Study, a massive NIH-funded project that enrolled nearly 51,000 women across the United States and Puerto Rico between 2003 and 2009. From that group, scientists built a case-cohort analysis comparing 1,609 women who later developed breast cancer against a subcohort of 2,269 women who did not.
Because blood was drawn years before any diagnosis, the study avoids a common trap in cancer research: reverse causation, where sick people’s bodies behave differently in ways that get mistaken for a cause. Here, the chemical levels came first and the cancer came later, which is exactly the kind of timeline doctors want to see before taking an exposure seriously.
The Honest Limits Of What This Study Can Prove
Every participant in the Sister Study had a sister previously diagnosed with breast cancer. That design helped researchers study disease efficiently, but it also means the women studied already carried a family history risk factor that most American women do not share. Results from this group may not translate exactly to women with no family history at all.
The study also cannot prove cause and effect. Blood PFAS levels and cancer risk moved together, but no one randomly assigned chemical exposure to test it directly, something ethically impossible to do to begin with. A brief but important caveat from contemporaneous reporting notes the findings do not establish causation on their own.
Where The Broader Science Gets Messier
Not every study agrees on how strong this link really is. A separate pooled analysis of multiple studies found a solid association for PFOA and ER-negative breast cancer, but the pooled estimate for PFOS came back weaker, with a confidence range that included the possibility of no increased risk at all. That kind of split result is common in chemical-exposure research and does not cancel out the NIH findings. It simply means PFOS needs more study before anyone calls the case closed.
Higher blood levels of two PFAS were associated with ER-negative breast cancer in a new study. Here's what you can do to limit your exposure to "forever chemicals." https://t.co/ofiwsSsa39
— WTOL 11 (@WTOL11Toledo) November 11, 2026
PFOA and PFOS have been used for decades in nonstick cookware, waterproof fabrics, firefighting foam, and food packaging. They earned the nickname “forever chemicals” because they barely break down in the environment or the human body. Manufacturers have phased out some uses, but legacy contamination lingers in soil, water, and blood samples nationwide.
What Comes Next For Women And Researchers
Scientists still need to confirm these results in other groups of women, especially those without a family history of breast cancer, and figure out whether risk rises steadily with higher exposure or jumps at a certain threshold. Until then, the sensible takeaway for readers is straightforward: these two chemicals deserve continued scrutiny, and reducing unnecessary exposure where practical is a reasonable precaution rather than an overreaction.
Sources:
mindbodygreen.com, nih.gov, clinicallab.com, aha.org
